Austin—[Updated and corrected, 2:36 p.m.] Dosh has added $40 million in new funding to further develop its mobile app that offers users cash back on certain purchases.
The money is Dosh’s Series B round of financing, and includes $20 million in... Read more »
Plymouth Growth Partners has made another investment in an Indiana tech company.
The Ann Arbor, MI-based venture capital fund has invested an undisclosed amount in Allied Payment Network, which is located in Fort Wayne, IN. Plymouth partner Jeff Barry says the... Read more »
Editas Medicine has the regulatory blessing to test its experimental gene-editing therapy in humans, and a $25 million check from its partner, Allergan, for hitting that milestone. But Editas will conduct the clinical trial without Katrine Bosley, the CRISPR biotech’s top... Read more »
San Antonio—Co-working space Geekdom is starting a short-term night program for people interested in learning about entrepreneurship.
The school, to be called The District, is accepting 36 students for its first six-week session, which begins Feb. 4. The program will... Read more »
Translate Bio’s plans to test a messenger RNA (mRNA) drug in patients who have a rare metabolic disorder have been halted by the FDA.
Lexington, MA-based Translate Bio (NASDAQ: TBIO) said Tuesday that the regulator verbally notified it of “additional... Read more »
Austin—Douglas Ferguson needed a change after his diagnosis of Type 1 diabetes at age 30.
As a career software engineer and technology executive, Ferguson has been a part of the Austin, TX, tech scene since its first heyday in the... Read more »
Texting has grown well beyond person-to-person communications. To remind customers about upcoming appointments or notify diners their restaurant tables are ready, for example, text messages have in many businesses replaced phone calls and light-up buzzer systems.
But text-based communications between businesses... Read more »
An Eli Lilly drug on the market for a rare form of cancer is now in limbo, after it failed a trial needed to retain the FDA approval the treatment, known as olaratumab (Lartruvo), won two years ago.
Lilly (NYSE: LLY... Read more »
Let’s catch up with the latest innovation news in Texas.
—TeVido, an Austin biotech, has raised $1.2 million to help fund a new facility in which the company can use a patient’s own cells to create personalized pigment cell... Read more »
[Updated 12:35pm ET with comments from Michael Gilman, Obsidian CEO, see below.] Bristol-Myers Squibb’s huge proposed buyout of Celgene earlier this month has left many in biotech circles concerned that the Summit, NJ, drugmaker’s days of creative, aggressive dealmaking... Read more »
A new tech education effort is forming in Detroit—created by Fontinalis Partners co-founder Chris Thomas—that focuses on teaching adult students the skills they need to compete for the increasingly large number of open jobs in the mobility industry.
Called the Detroit... Read more »
The partial government shutdown, now the longest in U.S. history, began to take a bite out of biotech this week, served with a hot side dish of confusion.
On Tuesday, Aimmune Therapeutics (NASDAQ: AIMT) said the shutdown would delay the... Read more »
The biggest news of the week from Wisconsin’s high-tech sectors was by far Brookfield-based Fiserv’s (NASDAQ: FISV) massive $22 billion deal to acquire First Data (NYSE: FDC). Meanwhile, here are some headlines and happenings you might’ve missed:
—Basic-code... Read more »